Claims
- 1. A composition comprising at least one compound selected from the group consisting of N-acetyl-3-chloroprocainamide and acid addition salts thereof.
- 2. A composition as defined in claim 1, comprising N-acetyl-3-chloroprocainamide.
- 3. A composition as defined in claim 1, comprising N-acetyl-3-chloroprocainamide hydrochloride.
- 4. A formulation for administration to a human or other animal comprising at least one compound selected from the group consisting of N-acetyl-3-chloroprocainamide and acid addition salts thereof, and a pharmaceutically acceptable carrier.
- 5. A method of inhibiting or killing tumor or cancer cells in a human or other animal, consisting essentially of treating the human or other animal with a composition selected from the group consisting of N-acetyl-3-chloroprocainamide, its acid addition salts, and mixtures thereof.
- 6. A method of inhibiting or killing tumor or cancer cells in a human or other animal, consisting essentially of treating the human or other animal with radiation or a chemotherapeutic agent together with a composition selected from the group consisting of N-acetyl-3-chloroprocainamide, its acid addition salts, and mixtures thereof, in an amount effective to enhance the cytotoxicity of the radiation or chemotherapeutic agent employed.
- 7. A method according to claim 6 of inhibiting or killing tumor or cancer cells in a human or other animal, consisting essentially of treating the human or other animal with a chemotherapeutic agent together with a composition selected from the group consisting of N-acetyl-3-chloroprocainamide, its acid addition salts, and mixtures thereof, in an amount effective to enhance the cytotoxicity of the chemotherapeutic agent employed.
- 8. A method according to claim 7, wherein said chemotherapeutic agent is cisplatin.
- 9. A method of treating inflammatory disorders comprising administering, to a human or other animal suffering from an inflammatory disorder, an amount of a composition selected from the group consisting of N-acetyl-3-chloroprocainamide, its acid addition salts, and mixtures thereof, said amount being effective to inhibit TNF-.alpha. production, thereby to inhibit an inflammatory response in said human or other animal.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. patent applications Ser. Nos. 08/807,071 now 6,028,111 and 08/807,497 (in which a divisional continued prosecution application under 37 C.F.R. .sctn.1.53(d) was filed Mar. 4, 1998), both of which were filed on Feb. 27, 1997, and both of which claim the right of priority of U.S. provisional patent application No. 60/013,072, filed Mar. 8, 1996. The entire disclosures of both of the aforesaid copending applications are incorporated herein by this reference.
Non-Patent Literature Citations (5)
Entry |
AN 1975:156684, Bundeanu et al. (1974). |
AN 1995:870709, Rummel et al. (1995). |
AN 1997:38135, Seelig et al. (1996). |
AN 1995:663483, Hill et al. (1995). |
AN 1990:417472, Robert-Piessard et al, (1990). |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
807071 |
Feb 1997 |
|
Parent |
807497 |
Feb 1997 |
|